Refractory period (sex) after orgasm in which further sexual stimulation does not produce excitement. While the refractory period varies widely among individuals, ranging from minutes to days, most men cannot achieve or maintain an erection during this time, and many perceive a psychological feeling of satisfaction and are temporarily uninterested in further sexual activity; the penis may be hypersensitive and further sexual stimulation may feel painful during this time frame. An increased infusion of the hormone oxytocin during ejaculation is believed to be chiefly responsible for the male refractory period, and the amount by which oxytocin is increased may affect the length of
Cabazitaxel mitoxantrone. Cabazitaxel was associated with more grade 3–4 neutropenia (81.7%) than mitoxantrone (58%). Cabazitaxel Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy. Cabazitaxel in combination with prednisone is a treatment option for hormone-refractory prostate cancer following docetaxel-based treatment. In a phase III trial with 755 men for the treatment of castration-resistant prostate cancer, median survival